New approaches to treatment of primary immunodeficiencies: Fixing mutations with chemicals

Current Opinion in Allergy and Clinical Immunology

Volumn 8, Issue 6, 2008, Pages 540-546

  Hu, Hailiang ^a   Gatti, Richard A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antisense oligonucleotides; Mutation targeted therapy; Pharmacogenetic treatment; Primary immunodeficiencies; Read through

Indexed keywords

AMINOGLYCOSIDE; ANTISENSE OLIGONUCLEOTIDE; ATM PROTEIN; GENTAMICIN; INTERLEUKIN 2 RECEPTOR GAMMA; PRO 051; PTC 124; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ANTISENSE THERAPY; ATAXIA TELANGIECTASIA; BETA THALASSEMIA; BLOOM SYNDROME; CHIMERAPLASTY; CYSTIC FIBROSIS; DUCHENNE MUSCULAR DYSTROPHY; FANCONI ANEMIA; FRAMESHIFT MUTATION; HUMAN; IMMUNE DEFICIENCY; MISMATCH REPAIR; MISSENSE MUTATION; NONHUMAN; NONSENSE MUTATION; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW; RNA SPLICING; SEVERE COMBINED IMMUNODEFICIENCY; WISKOTT ALDRICH SYNDROME;

ANIMALS; BLOOD-BRAIN BARRIER; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; LEUKOCYTES; MUTATION; NEURONS; OLIGONUCLEOTIDES, ANTISENSE; OXADIAZOLES; TARGETED GENE REPAIR;

EID: 56749150599     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328314b63b     Document Type: Review

References (51)

1. Fischer A. Human primary immunodeficiency diseases. Immunity 2007; 27:835-845.
2. Marodi L, Notarangelo LD. Immunological and genetic bases of new primary immunodeficiencies. Nat Rev Immunol 2007; 7:851-861.
3. Geha RS, Notarangelo LD, Casanova JL, et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 2007; 120:776-794. A comprehensive update on the classification of primary immunodeficiencies and the responsible genes. This is the official classification of the world body I.U.I.S.
4. Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res 2007; 38:122-132.
5. Gatti RA, Meuwissen HJ, Allen HD, et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968; 2:1366-1369.
6. Notarangelo LD, Forino C, Mazzolari E. Stem cell transplantation in primary immunodeficiencies. Curr Opin Allergy Clin Immunol 2006; 6:443-448.
7. Dvorak CC, Cowan MJ. Hematopoietic stem cell transplantation for primary immunodeficiency disease. Bone Marrow Transplant 2008; 41:119-126.
8. Chinen J, Puck JM. Perspectives of gene therapy for primary immunodeficiencies. Curr Opin Allergy Clin Immunol 2004; 4:523-527.
9. Aiuti A, Bachoud-Levi AC, Blesch A, et al. Progress and prospects: gene therapy clinical trials (part 2). Gene Ther 2007; 14:1555-1563.
10. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LM02-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302:415-419.
11. Zhang XB, Beard BC, Trobridge GD, et al. High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector. J Clin Invest 2008; 118:1502-1510.
12. Mitui M, Nahas S, Du LT, et al. Functional and computational assessment of missense variants in the ATM gene: mutations with increased cancer risk. Hum Mut. doi: 10.1002/humu.20805. [Epub ahead of print] This is the first attempt to evaluate heterozygous nonsynonymous DNA changes by stably transfecting each allele into a single host cell so that functional consequences can be evaluated in detail and compared to clinical phenotypes.
13. Orro A, Guffanti G, Salvi E, et al. SNPLims: a data management system for genome wide association studies. BMC Bioinformatics 2008; 9 (Suppl 2):S13.
14. Knerr V, Grimbacher B. Primary immunodeficiency registries. Curr Opin Allergy Clin Immunol 2007; 7:475-480.
15. Kellermayer R. Translational readthrough induction of pathogenic nonsense mutations. Eur J Med Genet 2006; 49:445-450.
16. Zingman LV, Park S, Olson TM, et al. Aminoglycoside-induced translational read-through in disease: overcoming nonsense mutations by pharmacogenetic therapy. Clin Pharmacol Ther 2007; 81:99-103. This is an excellent overview of genetic disease with nonsense mutations treated by aminoglycosides in vitro and in vivo.
17. Burke JF, Mogg AE. Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res 1985; 13:6265-6272.
18. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003; 349:1433-1441.
19. Politano L, Nigro G, Nigra V, et al. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol 2003; 22:15-21.
20. James PD, Raut S, Rivard GE, et al. Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood 2005; 106:3043-3048.
21. Lai CH, Chun HH, Nahas SA, et al. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci U S A 2004; 101:15676-15681.
22. Nudelman I, Rebibo-Sabbah A, Shallom-Shezifi D, et al. Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations. Bioorg Med Chem Lett 2006; 16:6310-6315.
23. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447:87-91. This important report identified and characterized a novel translational read-through compound PTC124 that can suppress nonsense mutations of Duchnne muscular dystrophy ex vivo in human and murine. PTC124 demonstrates a new, non-toxic, and bioavailable small-molecule drug for nonsense mutations, which has many implications for other genetic diseases.
24. Du M, Liu X, Welch EM, et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci U S A 2008; 105:2064-2069.
25. Du L, Lai CH, Concannon P, Gatti RA. Rapid screen for truncating ATM mutations by PTT-ELISA. Mutat Res 2008; 640:139-144.
26. Linde L, Boelz S, Nissim-Rafinia M, et al. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest 2007; 117:683-692. This study showed that nonsense-mediated decay was a major molecular mechanism to control patients' response to gentamicin and suggested that manipulation of NMD might be useful clinically.
27. Holbrook JA, Neu-Yilik G, Hentze MW, Kulozik AE. Nonsense-mediated decay approaches the clinic. Nat Genet 2004; 36:801-808.
28. Vacek M, Sazani P, Kole R. Antisense-mediated redirection of mRNA splicing. Cell Mol Life Sci 2003; 60:825-833.
29. Eng L, Coutinho G, Nahas S, et al. Nonclassical splicing mutations in the coding and noncoding regions of the ATM gene: maximum entropy estimates of splice junction strengths. Hum Mutat 2004; 23:67-76.
30. Burrows NP, Nicholls AC, Richards AJ, et al. A point mutation in an intronic branch site results in aberrant splicing of COL5A1 and in Ehlers-Danlos syndrome type II in two British families. Am J Hum Genet 1998; 63:390-398.
31. Di Leo E, Panico F, Tarugi P, et al. A point mutation in the lariat branch point of intron 6 of NPC1 as the cause of abnormal premRNA splicing in Niemann-Pick type C disease. Hum Mutat 2004; 24:440.
32. Du L, Pollard JM, Gatti RA. Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense morpholino oligonucleotides. Proc Natl Acad Sci U S A 2007; 104:6007-6012. This study confirmed the ability of antisense oligonucleotides to correct splicing mutations in primary immunodeficiency diseases.
33. Marshall NB, Oda SK, London CA, et al. Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter premRNA splicing. J Immunol Methods 2007; 325:114-126.
34. Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007; 448:39-43. This important study shows small RNA can be delivered across the blood-brain barrier to central nervous system with a Rabies virus glycoprotein peptide. This has broad implications to treatment of neurodegenerative genetic diseases.
35. Chun HH, Sun X, Nahas SA, et al. Improved diagnostic testing for ataxia-telangiectasia by immunoblotting of nuclear lysates for ATM protein expression. Mol Genet Metab 2003; 80:437-443.
36. Gatti RA, Boder E, Good RA. Immunodeficiency, radiosensitivity, and the XCIND syndrome. Immunol Res 2007; 38:87-101.
37. Urnov FD, Miller JC, Lee YL, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005; 435:646-651.
38. Miller JC, Holmes MC, Wang J, et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 2007; 25:778-785.
39. Lombardo A, Genovese P, Beausejour CM, et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007; 25:1298-1306.
40. van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007; 357:2677-2686. This clinical trial illustrated antisense oligonucleotide- mediated exon skipping for correcting frameshift mutations.
41. Ellis NA, Ciocci S, German J, Back mutation can produce phenotype reversion in Bloom syndrome somatic cells. Hum Genet 2001; 108:167-173.
42. Wada T, Konno A, Schurman SH, et al. Second-site mutation in the Wiskott-Aldrich syndrome (WAS) protein gene causes somatic mosaicism in two WAS siblings. J Clin Invest 2003; 111:1389-1397.
43. Wada T, Toma T, Okamoto H, et al. Oligoclonal expansion of T lymphocytes with multiple second-site mutations leads to Omenn syndrome in a patient with RAG1-deficient severe combined immunodeficiency. Blood 2005; 106:2099-2101.
44. Kalb R, Neveling K, Hoehn H, et al. Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype. Am J Hum Genet 2007; 80:895-910.
45. Hirschhorn R. In vivo reversion to normal of inherited mutations in humans. J Med Genet 2003; 40:721-728.
46. Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005; 115:2564-2571.
47. Vogt G, Vogt B, Chuzhanova N, et al. Gain-of-glycosylation mutations. Curr Opin Genet Dev 2007; 17:245-251.
48. Vogt G, Chapgier A, Yang K, et al. Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nat Genet 2005; 37:692-700.
49. Freeze HH. Novel perspectives on glycosylation and human disease. Curr Mol Med 2007; 7:387.
50. Bertoni C. Clinical approaches in the treatment of Duchenne muscular dystrophy (DMD) using oligonucleotides. Front Biosci 2008; 13:517-527.
51. Roberts J, Palma E, Sazani P, et al. Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol Ther 2006; 14:471-475.